Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1038)	11/12/1998 9:06:00 PM
From: chirodoc	Read Replies (1) \| Respond to of 1722

SAN DIEGO -- Potential billion-dollar superaspirins aside, this American College of Rheumatology conference is Enbrel's show. Back to Superaspirin Monsanto's (MTC:NYSE) Searle unit had more data on Celebrex, the superaspirin that is regarded as one of the next billion-dollar drugs. Merck's (MRK:NYSE) Vioxx is the other. The story of the COX-2 inhibitors, or superaspirins, is that they kill pain as well as other nonsteroidal anti-inflammatory drugs, but they don't cause the gastrointestinal bleeding that kills several thousand people each year. In the study presented Wednesday afternoon, Celebrex caused four stomach ulcers out of 212 patients, compared with 15 of 218 patients in the control group. The rate of upset stomach and abdominal pain wasn't starkly different between groups. Initially, Wall Street analysts think that the drug will be used for chronic pain and not by the weekend warriors who sprain their ankles and go to the hospital. But that still means big numbers, according to analysts.